{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"22.8","value":"15.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"}],"units":"Participants"}],"description":"Complete Response (CR): \\>75% decrease in size aggregate of nodal index lesions (large and small), complete disappearance of extranodal and non-index lesions; total disappearance of clinical disease including skin involvement; disease-related signs and symptoms, normalization of biochemical abnormalities and reduction in size of spleen or liver so no longer palpable. Unconfirmed CR: all above criteria except all nodal index lesions must have regressed \\>75% in the sum of the product diameters (SPD) from baseline. Individual nodes previously confluent must have regressed by \\>75% in their SPD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG000","title":"Romidepsin"}],"paramType":"NUMBER","populationDescription":"Histologically Confirmed Population, comprised all enrolled patients who received at least 1 dose of study treatment and who had histopathologically confirmed peripheral T-cell lymphoma(s). Patients who discontinued prior to any response evaluation or who had no post-baseline assessment of response were classified as non-responders.","reportingStatus":"POSTED","timeFrame":"Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.","title":"Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an Independent Review Committee","type":"PRIMARY","unitOfMeasure":"percentage of participants"}